Annual Report 2006 - Boehringer Ingelheim

More documents

Recommendations

Info

Treatment modalities used to relieve bothersome LUTS/BPH are designed to reduce the static and/ or dynamic component of obstruction and to improve the quality of life. Pharmacological therapy with flomax®/alna® (tamsulosin), an α1-receptor antagonist, is indicated for the treatment of this condition and provides effective and well-tolerated improve- ment of the symptoms. It relieves obstruction by relaxing smooth muscles in the prostate and urethra improving voiding symptoms. It also improves storage symptoms in which bladder instability plays an important role. After the launch of the 0.4 mg capsule in 1996, Boehringer Ingelheim and its partner Astellas developed a new tablet formulation using the technology ocas® (Oral Controlled Absorption System) to further optimise pharmacological therapy for LUTS/BPH. This system provides effective symptom control during daytime and nighttime, a very good tolerability and excellent convenience for the patient (e.g. once-daily dosing without the need of dose adjustment, medication intake independent of meals). flomax®/alna®, using the ocas® technology, has been available since 2005 in Germany, Spain and Switzerland. In 2006, it was launched in Portugal, France, Canada and Greece. The capsule formulation started to lose patent protection in several countries in March 2006. In the USA, patent protection will continue until October 2009. flomax®/alna® capsules and ocas® tablets generated net sales of EUR 922 million, an increase of 28 % over 2005, placing the medication third in Boehringer Ingelheim’s Human Pharmaceuticals sales ranking. Stress urinary incontinence Stress urinary incontinence (SUI) is the involun- tary loss of urine on effort or exertion, or on sneezing or coughing. Around 97 % of SUI patients are female, but less than half of the women suf- fering from this condition seek treatment. yentreve®/ariclaim®, with the active ingredient of duloxetine, is approved in the EU for the treatment of women with moderate to severe SUI. In 2006, it was jointly commercialised in several European countries and Mexico by Eli Lilly and Company and Boehringer Ingelheim. yentreve®/ ariclaim® generated revenues of EUR 4 million in 2006. Boehringer Ingelheim and Eli Lilly and Company (USA) jointly decided in February 2006 to change the contractual agreements for yentreve®/ ariclaim®. Eli Lilly and Company took over sole worldwide commercialisation rights for the medication for SUI and potential future, related urinary incontinence indications, effective as of 15 Janu- ary 2007. Oncology Every year, more than ten million people find themselves grappling with the medical uncertainties and emotional upheaval of a newly diagnosed cancer. Fortunately, an increasing number of patients benefit from surgery, radiation and pharmacological medicines, with a complete cure possible in about 60 % of cases. If the cancer has spread throughout the body, the hurdles for effective therapies become higher, but even then serving patients cure or disease modification with longer survival and better quality of life is possible with innovative, targeted medicines that offer more efficacy and better tolerability to patients. Prescription Medicines 9
0 Our clinical studies in oncology We have embarked on the discovery and development of innovative medicines for some of the most common cancers. Since 2000, research conducted at Boehringer Ingelheim Austria has resulted in promising drug candidates moving into advanced clinical development. We are conducting clinical studies of phase II for compounds interfering with essential drivers of tumour growth: A) aberrant growth signalling through activity of epidermal growth factor receptor (EGFR) and human epidermal growth factor (HER 2), B) supply of oxygen and nutrients to cancer cells by the development of new blood vessels to the tumour (neoangiogenesis), and C) targeting inhibition of the uncontrolled cell division (mitosis). Current phase I / II target indications for our oral compounds in antiangiogenesis and signal transduction, and our intravenous cell-cycle inhibitor, include non-small-cell lung cancer, breast cancer, colorectal cancer, prostate cancer, ovarian cancer, leukaemia and lymphomas. We are confident that the continued good patient accrual into our phase II studies will allow us to establish first proofs of efficacy towards the end of Boehringer Ingelheim A n n u A l R e p o R t 2 0 0 6 Cell-cycle kinases are cellular proteins that promote the process of cell division. Boehringer Ingelheim’s first-inclass investigational compound BI 2536 (light blue) seems to effectively block such a cell-cycle kinase (the polo-like kinase, Plk-1) at its active site, leading to tumour growth inhibition and tumour regression. 2007 and that the innovative features of our molecules, once confirmed in phase III trials, will offer improved treatment choices to cancer patients. Our R & D in oncology The sequencing of the human genome and detailed studies of genetic changes in human cancer cells, known as oncogenome signature typing, have accelerated the identification of mutations and the knowledge of the faulty cellular circuitry that underlie the aberrant growth, invasion and metastasis of cancerous tissues in the body. Moreover, they provide important clues to new drug targets and the best match-up of new drugs with the patients whose cancers are most likely to respond to the drugs, a process called biomarker-guided drug development or customised cancer therapy. New further compounds have entered development to strengthen our emerging oncology pipeline and we are continuing our efforts to develop monoclonal antibody-based drug candidates. As part of our strategic collaboration with MorphoSys on human antibodies, we have exer- cised an option for optimising a therapeutic
Page 1 and 2:
Value through Innovation Annual Rep
Page 3 and 4:
Contents 1 Value Through Innovation
Page 5 and 6:
The Shareholders’ Perspective Dea
Page 7 and 8:
Key Aspects of 2006 2006 was again
Page 9 and 10:
This growth was clearly restrained
Page 11 and 12:
Shareholders’ Committee Dr Heribe
Page 13 and 14:
“There is help” “The woman wh
Page 15 and 16:
1 continued from page 10 A Kenyan m
Page 17 and 18:
1 Our people In pursuing our vision
Page 19 and 20:
Company childcare enters new territ
Page 21 and 22: 1 Caring for our neighbours We are
Page 23 and 24: 0 Children from St Margaret Clither
Page 25 and 26: Our environment & employee safety A
Page 27 and 28: thanks to the use of the wood-fired
Page 29 and 30: Our goals We shall continue to inve
Page 31 and 32: Targeting tomorrow’s therapies Th
Page 33 and 34: 0 continued from page 28 “Boehrin
Page 35 and 36: Our R & D strategy Research and dev
Page 37 and 38: Ridgefield, USA Cardiovascular, imm
Page 39 and 40: Vienna, Austria Oncology Boehringer
Page 41 and 42: Our expertise in landmark studies L
Page 43 and 44: From mind to man - the R & D proces
Page 45 and 46: New biological entities (NBE) One o
Page 47 and 48: The development of our businesses W
Page 49: Rin Fujima, Kyoto, Japan, suffers f
Page 52 and 53: Human Pharmaceuticals Branded presc
Page 54 and 55: cal exercise capacity and the reduc
Page 56 and 57: “Like a great round of golf“
Page 58 and 59: gives patients a better chance of g
Page 60 and 61: aptivus® was launched in the USA i
Page 62 and 63: enzymes, such as the HCV serine pro
Page 64 and 65: Børge Madsen, Copenhagen, Denmark.
Page 66 and 67: Cardiovascular diseases Despite sig
Page 68 and 69: actilyse® is the first and only th
Page 70 and 71: fibrillation in some 40 countries i
Page 74 and 75: HuCAL antibody directed against a c
Page 76 and 77: hand, the end of exclusivity in Eur
Page 78 and 79: Generic Prescription Medicines The
Page 80 and 81: Ben Venue - a world leader in steri
Page 82 and 83: Mara Lovera, Buenos Aires, Argentin
Page 84 and 85: Consumer Health Care Our Consumer H
Page 86 and 87: Switching reinforces the trend towa
Page 88 and 89: Alexander (left) and Christopher pl
Page 90 and 91: Animal Health The sound progress of
Page 92 and 93: located, trained and placed with fi
Page 94 and 95: Our Customer Orientation Our custom
Page 96 and 97: On a biopharmaceutical compound’s
Page 98 and 99: Pharmaceuticals Production Our Phar
Page 100 and 101: Counterfeits - a real threat for pa
Page 102 and 103: Group Management Report 2006
Page 104 and 105: companies lost their patent protect
Page 106 and 107: To summarise, we see the success of
Page 108 and 109: Production Production sites belongi
Page 110 and 111: In the area of HIV/AIDS therapy, we
Page 112 and 113: only 2 %. The region’s overall ne
Page 114 and 115: of the cash flow, which rose by EUR
Page 116 and 117: Report on expected developments The
Page 118 and 119: Consolidated Financial Statements 2
Page 120 and 121: C. H. Boehringer Sohn Grundstücksv
Page 122 and 123:
C. H. Boehringer Sohn, Ingelheim Co
Page 124 and 125:
C. H. Boehringer Sohn, Ingelheim St
Page 126 and 127:
The following subsidiaries were exe
Page 128 and 129:
2 Accounting and evaluation methods
Page 130 and 131:
3 Notes to the consolidated balance
Page 132 and 133:
3.3 Financial assets (in millions o
Page 134 and 135:
Pension provisions Boehringer Ingel
Page 136 and 137:
4 Notes to the consolidated profit
Page 138 and 139:
4.7 Holding income (in millions of
Page 140 and 141:
Other mandatory disclosures accordi
Page 142 and 143:
Derivative financial instruments at
Page 144 and 145:
With the following exception, our a
Page 146 and 147:
Product name Active ingredient Indi
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Comparison of Balance Sheets/ Finan
show all

Annual Report 2006 - Boehringer Ingelheim

Create successful ePaper yourself

Delete template?

Save as template?